Arvinas
Manufacturing · Connecticut, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
5 Science Park # 395, New Haven, Connect...Phone Number
(203) 535-1456Website
www.arvinas.comRevenue
$89.4 MillionStock Symbol
ARVNIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Arvinas
Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies through its proprietary PROTAC® platform. The company focuses on discovering and developing innovative medicines for cancer, neurology, and other serious diseases by selectively degrading disease-causing proteins. Its research-driven approach aims to expand treatment possibilities for patients with difficult-to-treat conditions.Explore more
Arvinas Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arvinas your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Arvinas has recently received funding, and reach out quickly before it becomes old news!
Click to see if Arvinas had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Arvinas
Check out if Arvinas is spiking on competitors!
Earning: See what the market has to say on Arvinas recently announced quarterly report
Arvinas, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Arvinas launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Arvinas has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Arvinas
Compare insights from companies similar to Arvinas, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Arvinas is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Arvinas is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Arvinas.
Arvinas financials insights
Gather financial insights about Arvinas, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Corporate Investment
$3.3M
Series A
$15M
2015
Series B
$41.6M
2018
Series C
$55M
Stock Offering
$120M
Arvinas Tech Stack
A closer look at the technologies used by Arvinas
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Engineering, Contingent Workforce, Sales, Outsourcing, Bioengineering, Chemical Engineering, Field /Outside Sales, Field Marketing
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Project
plans to share additional biomarker data from the ARV-102 Phase I trial later this year and initiate both a Phase I-B and a Phase II trial in patients with progressive supranuclear palsy (PSP) this year.
Medical Research, Clinical Operations
Partnership
Partnership, Product Management, Business Development, Intellectual Property, Legal Affairs, Pharmaceuticals, Manufacturing Operations
Arvinas News & Media
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET.[8-K] ARVINAS, INC. Reports Material Event - ARVN - Stock Titan
Arvinas, Inc. announced that chief medical officer Noah Berkowitz, M.D., Ph.D. will leave the company, with his employment ending on July 3, 2026.Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
NEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has recently joined the LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson’s Precision Medicine Initiative (PPMI), both supported by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).Arvinas to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Arvinas
Sign Up For FreeTo access detailed company insights
Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies through its proprietary PROTAC® platform. The company focuses on discovering and developing innovative medicines for cancer, neurology, and other serious diseases by selectively degrading disease-causing proteins. Its research-driven approach aims to... Read More
